Maximize virus uptake with transduction enhancers from the experts
Restricted uptake of virus particles often lowers the success of gene or shRNA expression and requires the application of higher viral titers. However, increasing the amount of viruses to boost expression can lead to toxic side effects in many cell types and makes the application unnecessarily costly.
SIRION BIOTECH’s unique BOOST™ products were developed to specifically enhance the efficiency of viral gene transfer into difficult to transduce mammalian and rodent cell. Virus uptake is significantly increased without toxicity, and the number of viral copies per cell can be titrated to meet optimum conditions.
LentiBOOST® – increase lentiviral transduction of difficult cell types, such as T- or B-cells, NK cells, and fibroblasts.. A real gamechanger for CAR-T cell experiments and R&D.
AdenoBOOST™ – make the most of your adenovirus batches by increasing the transduction efficiency 50-fold.
LentiBOOST® is a highly effective, non-cytotoxic transduction enhancer for preclinical and clinical application of lentiviral vectors. It is a universal polaxamer-based, receptor-independent adjuvant which facilitates fusion of lenitivrus particles with cell membrane, significantly increasing transduction efficiency.
LentiBOOST® can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells, NK cells, fibroblasts, and hard-to-transduce murine T cells. These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.
In the demonstration above, LentiBOOST™ increases transduction by a factor of 5.
LentiBOOST™ Pharma grade
For use in preclinical research and process development only. For quotes and further requests on this technology, please inquire with firstname.lastname@example.org.
LentiBOOST™ GMP grade
For use in clinical stage protocols. Currently included in more than 20 Phase III and I/II clinical trials in the US and in Europe. Licensing options for Clinical/Commercial Use and Development are available.
Please inquire with email@example.com.
Benefits for Drug Development at a glance
Improved lentiviral transduction efficiency, up to 90%.
⇒ Increased expression levels of therapeutic protein have a favorable effect on success rates of clinical trials.
Positive impact on cell proliferation for CD34+ and T cells.
⇒ Reduced cost of goods, optimized and stable transgenic cell manufacturing.
Titratable vector copy numbers per cell.
⇒ Strong and durable therapeutic protein expression, in line with FDA/EMA criteria for ATMPs production.
Successful track record of integration into clinical trials (III and I/II) in the US and Europe.
⇒ Proven lack of cell toxicity and prior clinical applications expedite IND filing.
GMP grade batches available.
⇒ With all necessary documentation for direct integration into clinical programs.
Read about LentiBOOST™ in the news.